Commitment to patient care and environmental sustainability
Chiesi, a family owned international pharmaceutical company, has been developing innovative medicines to treat respiratory diseases for more than 30 years. During this time, we have supported the international and UK agenda for reducing the environmental impact of inhalers. From the outset, Chiesi supported the implementation of the Montreal Protocol and Kigali Amendment, as well as the UK Transition Strategy for CFC-based metered dose inhalers (MDIs).1
We have long been at the forefront of the development and commercialisation of hydrofluoroalkane (HFA) formulations in Europe, while striving to deliver the highest standards in patient and health outcomes. We were one of the first companies to move from Chlorofluorocarbons (CFCs) to HFA based technologies.
In October 2017, the parliamentary Environmental Audit Committee (EAC) launched its inquiry into the UK’s progress on reducing fluorinated gas (F-gas) emissions, a part of which looked at the use of metered dose inhalers, which are widely used for the treatment and management of respiratory diseases, such as asthma and chronic obstructive pulmonary disease. The EAC published its findings on the UK Progress on Reducing F-gas Emissions, April 2018. The EAC report can be found following this link https://publications.parliament.uk/pa/cm201719/cmselect/cmenvaud/469/469.pdf
Details of our patient safety and environmental sustainability considerations in response to the EAC inquiry can be found within the ‘Latest evidence’ section of the EAC website https://www.parliament.uk/business/committees/committees-a-z/commons-select/environmental-audit-committee/inquiries/parliament-2017/uk-progress-on-reducing-f-gas-emissions-17-19/